Skip to main content
Article thumbnail
Location of Repository

The effects of oligosaccharides and probiotic bacteria on the intestinal microflora and vancomycin-resistant enterococcus

By Franco Andrea Bruno

Abstract

The objectives of this study were: 1) to investigate the effect of bifidobacteria and oligosaccharides on their role in suppressing the growth of pathogenic bacteria in vitro, 2) to investigate the growth, viability and activity of Bifidobacterium spp. in skim milk containing prebiotics, 3) to investigate the effect of storage temperature on freeze-dried bifidobacteria with inulin and commercial probiotic products, 4) to investigate the effect of humans consuming capsules containing freeze-dried bifidobacteria and inulin on several gastrointestinal indices, and 5) to investigate the effect of probiotic bacteria on the suppression of vancomycin-resistant enterococcus in vitro

Topics: 1108 Medical Microbiology, School of Engineering and Science, 0304 Medicinal and Bimolecular Chemistry, Intestines, Microbiology, Microorganisms, Oligosaccharides, Enterococcal infections, bifidobacteria, invitro, gastrointestinal, vancomycin
Year: 2004
OAI identifier: oai:eprints.vu.edu.au:15574

Suggested articles

Citations

  1. (2001). A comparative in vitro evaluation of the fermentation properties of prebiotic oligosaccharides.
  2. A medium for the cultivation of Lactobacilli.
  3. (1988). A specific and sensitive method for the quantitative deteraiination of nitrite.
  4. (1984). Abnormal intestinal motility as an etiological factor in inflammatory bowel disease.
  5. (1998). Adherence of probiotic bacteria to human colonic cells.
  6. (1995). AMC agar-A composite medium for selective enumeration of Bifidobacterium longum.
  7. (1998). An overview of probiotics, prebiotics and synbiotics in the functional food concept: perspectives and future strategies.
  8. (1997). Analysis of fecal populations of bifidobacteria and lactobacilli and investigation of the immunological responses of their human hosts to the predominant strain.
  9. (1985). Antibacterial activity associated with Bifidobacterium bifidum- II. Cult Dairy Prod.
  10. (1998). Antibacterial efficacy of nisin against multidmg-resistant Gram-positive pathogens.
  11. (2003). Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Resistant Enterococci Susceptibility Study (NAVRESS).
  12. (1998). Antibiotic resistance pattems of enterococci and occunence of vancomycin-resistant enterococci in raw minced beef and pork in Germany.
  13. (1993). Antimicrobial susceptibility ofbifidobacteria.
  14. (1998). Antimutagenic properties of probiotic bacteria and of organic acids.
  15. (2003). Applications in fermented milks in Encycl.
  16. (2000). Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and prebiotics for human use.
  17. (1925). Bacillus bifidus; its characters and isolation from the intestine of infants.///j^g.
  18. (2001). Bacteriocin production in vancomycin-resistant and vancomycin susceptible enterococcus isolates of different origins.
  19. (1957). Bergey's Manual of Determinative Bacteriology (7**" edn). Williams and Wilkins,
  20. (1990). Bifidobacteria and bifidogenic factors.
  21. (1990). Bifidobacteria as possible dietary adjuncts in cultured dairy products- A review.
  22. (1993). Bifidobacteria in dairy products.
  23. (1997). Bifidobacteria longum and lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats.
  24. (1995). Bifidobacteria may have role as imniunomodulator in intestines.
  25. (1993). Bifidobacteria: Activity and potential benefits.
  26. (1991). Bifidobacteria: Their potential for use in American dairy products. Food Tech.
  27. (1997). Bifidobacterium longum, a lactic-acid producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis.
  28. (1999). Bifidobacterium spp. and Lactobacillus acidophilus: biological, biochemical, technological and therapeutical properties relevant for use as probiotics.
  29. (1996). Bile tolerance, taurocholate deconjugation and cholesterol removal by Lactobacillus acidophilus and Bifidobacterium spp.
  30. (2002). Changes in predominant bacterial faeces with age and with Clostridium difficile infection.
  31. (1999). Changes of fennentation pathways of fecal microbial communities associated with a drug treatment that increases dietary starch in the human colon.
  32. (1995). Characterisation of fmctose 6 phosphate phosphoketolases purified from Bifidobacterium species.
  33. (1999). Characteristics of bacteriocin like inhibitory substances produced by Lactobacillus acidophilus (BDLA-1, 2409 and MOLA-2), Lactobacillus fermentum (5174) and Lactobacillus plantarum (2903).
  34. (1997). Characteristics of bacteriocin produced by Lactobacillus acidophilus LA-1.
  35. (1989). Chemical characterisation of an antimicrobial substance produced by Lactobacillus reuteri.
  36. (2002). Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ.
  37. (2001). Classification and identification of enterococci: a comparative phenotypic, genotypic, and vibrational spectroscopic study.
  38. (2001). Clinical applications of probiotic agents.
  39. (2002). Clinical significance of the emergence of bacterial resistance in the hospital environment.
  40. (1987). Competitive exclusion of salmonellas from the chick caecum using a defined mixture of bacterial isolates from the caecal microflora of an aduft bird.
  41. (1998). Consumption of exogenous bifidobacteria does not alter fecal bifidobacteria and breath hydrogen excretion in humans.
  42. (2000). Consumption of fermented and nonfennented dairy products: effects on cholesterol concentrations and metabolism.
  43. (1998). Continuous culture selection ofbifidobacteria and lactobacilli from human faecal samples using fi-uctooligosaccharides as selective substrate.
  44. (1996). Crystal stmcture of vancomycin.
  45. (1990). Detection of Bifidobacterium species by enzymatic methods.
  46. (1999). Development of a PCR assay for rapid detection of enterococci.
  47. (1986). Development of intestinal microflora in humans and animals.
  48. (1999). Developmental microbial ecology of the neonatal gastrointestinal tract.
  49. (1973). Die Faekalflora bei Meschen. 1. Mitteilung: Die Zusammensetzung der Faekalflora der vershiedenen Altersgmppen. Zentralblatt fiir Bakteriologie, Parasitenkunde, Infektionskrakheiten und Hygiene, Abteilung 1. Originale A223:
  50. (1998). Diet and bacterial colonization: Role of probiotics and prebiotics.
  51. (1995). Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics.
  52. (1999). Dietary modulation of the human gut microflora using the prebiotics oligofinctose and inulin.
  53. (1999). Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-genetargeted species-specific primers.
  54. (1965). DNA base composition and classification. Application to group ofbifidobacteria and to related genera.
  55. (1999). Dose-response effects of inulin and oligofi-uctose on intestinal bifidogenesis effects.
  56. (1998). Ecological and physiological studies on large intestinal bacteria in relation to production and of hydrolytic reductive enzymes involved in formation of genotoxic metabolites.
  57. (1987). Ecology of Bifidobacterium in the human intestinal flora.
  58. (1997). Effect of Bifidobacterium longum BB536 administration on the intestinal environment, defecation frequency and fecal characteristics of human volunteers.
  59. (1996). Effect of bifidogenic factors on growth characteristics ofbifidobacteria in infant fonnulas.
  60. (1995). Effect of bifiidobaderia on nitrates and nitrosamines.
  61. (1980). Effect of diet and Lactobacillus acidophilus supplements on human faecal bacterial enzymes.
  62. (1987). Effect of fructooligosaccharides on intestinal microflora. Die Nahrung.
  63. (1996). Effect of immobilisation in alginate on the stabihty of freeze-dried Bifidobacterium longum.
  64. (1988). Effect of Isomalto-oligosaccharides on human fecal flora.
  65. (1992). Effect of lactulolse on the composition and metabolic activity of the human faecal flora.
  66. (1997). Effect of yogurt containing Bifidobacterium longum BB536 on the intestinal environment, fecal characteristics and defecation frequency: A comparison with standard yogurt, ^zo^cr.
  67. (1994). Effective dose of lactosucrose on faecal flora and faecal metabolites of humans.
  68. (1983). Effects of administration of TOS and Bifidobacterium breve 4006 on the human fecal flora.
  69. (2002). Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.
  70. (2002). Effects of consumption of probiotics and prebiotics on semm lipid levels in humans.
  71. (1990). Effects of culture condensate of Bifidobacterium longum (MB) of feed efficiency, morphology of intestinal epithehal cells, and fecal microflora of rats.
  72. (1998). Effects of different test conditions on mics of food animal growth-promoting antibacterial agents for enterococci.
  73. (1986). Effects of fmctooligosaccharides on intestinal flora and human health.
  74. (2000). Effects of probiotic bacteria on diarrhoea, lipid metabolism, and carcinogenesis: a review of papers published between
  75. (1993). Effects of the in vitro fennentation of oligofmctose and inulin by bacteria growing in the human large intestine.
  76. (1998). Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates.
  77. (1994). Enrichment ofbifidobacteria from human gut contents by ohgofmctose using continuous culture.
  78. Enterococci with glycopeptide resistance in turkeys, turkey farmers, turkey slaughters, and (sub)urban residents in the south of the Netheriands: Evidence for transmission of vancomycin resistance from animals to humans?
  79. (2000). Enterococci with reduced susceptibility to vancomycin in New Zealand.
  80. (1984). Enterococcus avium nom. rev., comb, nov.; E. casselifiavus nom. rev., comb, nov.; E. durans nom. rev., comb, nov.; E. gallinarum comb, nov.; and E. malodoratus sp.
  81. (1998). Epidemiologic evaluation of antimicrobial resistance in community-acquired enterococci.
  82. (1994). Evaluation of media for enumeration of Bifidobacterium adolescentis, B. infantis and B. longum from pure culture.
  83. (1996). Evaluation of media for selective enumeration of Streptococcus thermophilus. Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus acidophilus
  84. (2002). Factors impacting on the problem of antibiotic resistance.
  85. (1974). Fecal Bacterial B-Glucuronidase: Control by diet.
  86. (2000). Fennentation of fmctooligosaccharides by lactic acid bacteria and bifidobacteria. Appl Environ.
  87. (1967). Fennentation of glucose, lactose, galactose, mannitol and xylose by bifidobacteria.
  88. (1998). Fennented milks and probiotics
  89. (1986). Genus Bifidobacterium. Pages 1418-1435 in Bergey's Manual of Systematic Bacteriology.
  90. (2000). Growth and viability of commercial Bifidobacterium spp. in skim milk containing oligosaccharides and inulin.
  91. (1996). Growth characteristics ofbifidobacteria in infant formulas.
  92. (2003). Health effects of probiotics and culture-containing dairy products in humans.
  93. (1998). hicorporation of cholesterol into the cellular membrane of Bifiidobacterium longum.
  94. (1994). hihibitory effect of Bifidobacterium longum cultures on the azoxymethane-induced abenant crypt foci fonnation and faecal bacterial Bglucuronidase.
  95. (1992). hitestinal flora and aging.
  96. (1995). hitestinal flora of populations that have a high risk of colon cancer.
  97. (1997). hnproving viability of Lactobacillus acidophilus and Bifidobacterium spp. in yogurt.
  98. (1995). Human colonic bacteria.
  99. (1996). Human colonic biota studied by ribosomal DNA sequence analysis.
  100. (1974). Human fecal flora: The nonnal flora of 20 Japanese-Hawaiians.
  101. (1999). Identification of enterococcus spp. with a biochemical key. Appl Environ. Microbiol 65(10):4425-4430.
  102. (1972). Identification of lactic acid bacteria, hi Identification Methods for Microbiologists
  103. (2002). Identification of probiotic cultures in food samples. Food Res.
  104. (1996). Improvement of lactose digestion in humans by ingestion of unfemiented milk containing Bifidobacterium longum.
  105. (2001). In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings.
  106. (2001). Incidence of vimlence factors and antibiotic resistance among enterococci isolated from food.
  107. (1999). Increase of intestinal Bifiidobacterium and suppression of coliform bacteria with short-term yogurt ingestion.
  108. (1993). Inhibition of Escherichia coli by bifidobacteria.
  109. (2002). Inhibition of pathogenic and putrefactive microorganisms by Bifidobacterium sp.
  110. (1996). Inhibitory effects of human-derived Bifidobacterium on pathogenic Escherichia coli serotype 0-111.
  111. (1993). Inliibitory effect of Bifidobacterium longum on colon, mammary and liver carcinogenesis induced by 2-amino-3-methyliniidazo [4,5-f] quinoline, a food mutagen.
  112. (1998). Inter-species differences in maximum specific growth rates and cell yields of bifidobacteria cultured on oligosaccharides and other simple carbohydrates.
  113. (1984). Intestinal flora in health and disease.
  114. (1924). La classification des bacteries lactiques.
  115. (1998). Lactic acid bacteria: Microbiology and functional aspects. (2"'' ed.)
  116. (1986). Lactulose and intestinal microflora in infant nutrition.
  117. (1998). Letters to the editor: Historical yearly usage of vancomycin.
  118. (2002). Metabolic characteristics of the faecal microflora in humans from three age groups.
  119. (1996). Metabolism of bifidogenic factors by gut flora-an overview.
  120. (1991). Methods for enumerating and propagating bifidobacteria.
  121. (1997). Modification of the intestinal microflora using probiotics and prebiotics.
  122. (2000). Modification of the phosphoketolase assay for rapid identification ofbifidobacteria.
  123. (1996). Molecular analysis of the composition of the bifidobacterial and lactobacillus microflora of humans. Appl Environ.
  124. (2003). Molecular characterisation of clinical and environmental isolates of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis from a teaching hospital.
  125. (1999). Molecular epidemiology of vancomycin-resistant enterococcus faecium in a large urban hospital over a 5-year period.
  126. (1973). New aspects of Salmonella infection in boiler production.
  127. (1994). Non-digestible oligosaccharides and bifidobacteria-implications for health.
  128. (2000). Nondigestible oligosaccharides.
  129. (1995). Nonnal microflora. An introduction to microbes inhabiting the human body. Chapman and Hall.
  130. (2002). Nurse's experience with vancomycin-resistant enterococci (VRE).
  131. (2003). Nutritional responses to the presence of inulin and oligofructose in the diets of domesticated animals: A review. Crit Rev.
  132. (2002). Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic.
  133. (2002). Patients in long-tenn care facilities: A reservoir for vancomycin-resistant enterococci.
  134. (1995). Physiological effects of Bifidobacterium longum BB536-in vitro tests and administration to humans and animals. Morinaga Milk Industry,
  135. (1998). Physiological effects of consumption of fmcto-oligosaccharides and transgalacto-ohgosaccharides.
  136. (1996). Pre- and syn-biotics with inulin and oligofmctose: promising developments in functional foods.
  137. (2001). Prebiotic digestion and fermentation.
  138. (2001). Prebiotics and probiotics: are they ftmctional foods?
  139. (1998). Prebiotics and synbiotics: concept and nutritional properties.
  140. (1999). Prebiotics In Probiotics: A critical review.
  141. Prebiotics, probiotics and human gut microbiology./7i/.
  142. (2000). Prebiotics: New developments in functional foods. Chandos Publishing Limited,
  143. (2001). Prebiotics: preferential subsfrates for specific genns?
  144. (2000). Probiotic bacteria: Selective enumeration and survival in dairy foods.
  145. (1991). Probiotic in human medicine.
  146. (1999). Probiotic spectra of lactic acid bacteria.
  147. (1999). Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health.
  148. (2001). Probiotics and safety.
  149. (1992). Probiotics for humans in Probotics: The scientific basis.
  150. (1989). Probiotics in man and animals.
  151. (2002). Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis.
  152. (2001). Probiotics inhuman disease.
  153. (1999). Probiotics: A critical review.
  154. (2001). Probiotics: Challenges and opportmiities.
  155. (2001). Probiotics: determinants of survival and growth in the gut.
  156. (1999). Probiotics: Scientific support for use.
  157. (1993). Probiotics: The scientific basis. Chapman and Hall.
  158. (2001). Probiotics:effects on immunity.
  159. (1965). Probiotics. Growth promoting factors produced by microorganisms.
  160. (1991). Prohferation ofbifidobacteria by oligosaccharides and their useftil effect on human health.
  161. (2002). Protective nutrients and functional foods for the gastrointestinal tract.
  162. (2001). Protective role of probiotics and prebiotics in colon cancer.
  163. (2003). Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients.
  164. (1998). Rapid identification of human intestinal bifidobacteria by 16s rRNA-targeted species- and group-specific primers.
  165. (1982). Recent frends in research on intestinal flora.
  166. Recherches sur la flore intestinale normale et pathologique du nourission. Thesis,
  167. (2001). Regulation of VanA- and VanB- Type glycopeptide resistance in enterococci.
  168. (2000). Relationships between enterococcal vimlence and antimicrobial resistance.
  169. (2002). Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci.
  170. (2001). Routine molecular identification of enterococci by gene-specific PCR and 16s ribosomal DNA sequencing.
  171. (1997). Selected ingestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in r&ts.
  172. (1999). Selection and design of probiotics.
  173. (1993). Selection ofbifidobacteria for use as dietary adjuncts in cultured dairy foods: II- Tolerance to stimulated pH of human stomachs.
  174. (1995). Selective stimulation of bifidobacteria in the human colon by oligofmctose and inulin.
  175. (2000). Significance of dietary modulation of intestinal flora and intestinal environment.
  176. (1990). Some chemical and physical properties of nisin, a smallprotein antibiotic produced by lactococcus lactis. Appl Environ.
  177. (2000). Specific detection of Bifidobacterium sfrains in a pharmaceutical probiotic product and m human feces by polymerase chain reaction.
  178. (1998). Studies of the intestinal microflora: A prerequisite for the development of probiotics.
  179. (1993). Substrate and lactic acid bacteria.
  180. (2000). Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp.
  181. (1996). Survival of bifidobacteria during refrigerated storage in presence of acid and hydrogen peroxide.
  182. (1992). Survival of bifidobacteria ingested via fennented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion.
  183. (1994). Survival of constitutive microflora in commercially fermented milk containing bifidobacteria during refrigerated storage.
  184. (1995). Survival of Lactobacillus acidophilus and Bifiidobacterium spp. in the presence of acid and bile salts.
  185. (1998). Survival of vancomycin-resistant and vancomycin-susceptible enterococci on diy surfaces.
  186. (1998). Susceptibility ofbifidobacteria to nisin.
  187. (2000). Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK,
  188. (1984). Taxonomy and ecology ofbifidobacteria.
  189. (2001). Taxonomy and important features of probiotic microorganisms in food and nutrition.
  190. (1998). Taxonomy and physiology of probiotic lactic acid bacteria.
  191. (1998). The bifidogenic nature of chicory inulin and its hydrolysis products.
  192. (1997). The C-terminal region of nisin is responsible for the initial interaction of nisin with the target membrane.
  193. (1984). The effect of milk and Lactobacillus feeding on human intestinal bacterial enzyme activity.
  194. (2001). The effect of nisin on the physiology of Bifiidobacterium thermophilum.
  195. (1984). The effect of oral administration of Lactobacillus and antibiotics on intestinal bacteria activity and chemical induction of large bowel tumour.
  196. (1999). The efficacy and safety of quinupristionydalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium.
  197. (2002). The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract.
  198. (1995). The genus Bifidobacterium in The genera of lactic acid
  199. (1993). The growth of Bifidobacterium longum in a wheybased medium and the viability of this organism in frozen yoghurt with low and high levels of developed acidity.
  200. (2002). The health benefits of probiotics. Food Aust.
  201. (2000). The human gut flora in nutrition and approaches for its dietary modulation.
  202. (1999). The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients.
  203. (1919). The lactic acid bacteria,
  204. (1988). The normal microflora; new concepts in health promotion.
  205. (1907). The prolongation of life.
  206. (1976). The relationship between diet and rat faecal bacterial enzymes imphcated in colon cancer.
  207. (1999). The role of intestinal bacteria in the causation and prevention of cancer: modulation by diet and probiotics.
  208. (1995). The role of lactic acid bacteria in colon cancer prevention.
  209. (2000). The role of probiotic cultures in the control of gastrointestinal health.
  210. (1937). The streptococci.
  211. (2003). Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections.
  212. (2002). Treatment options for vancomycin-resistant enterococcal infections.
  213. (1957). Untersuchungen uber die gram-positive stuhlflora des bmstmilchkindes.
  214. (1998). Use of enzyme tests in characterisation and identification of aerobic and facultatively anaerobic gram-positive cocci.
  215. (1998). Use of molecular and reference susceptibility testing methods in a multicenter evaluation of microscan dried ovemight gram-positive mic panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci.
  216. (2001). Vancomycin-resistant enterococci colonization in patients at seven hemodialysis centers.
  217. (1996). Vancomycin-resistant enterococci from nosocomial community and animal sources in the United States.
  218. (2000). Vancomycin-resistant enterococci: New threat in renal patients.
  219. (1997). Vancomycin-resistant enterococcus. Infectious disease clinics of North America.
  220. (1969). Vergleichende Untershungen uber die Bifidobakterien aus dem Verdauugstrakt von Menschen und Tieren. Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrrankheiten und Hygiene, Abteilung 1.
  221. (1963). Vergleichende Untersuchungen uber die Bifidus-Flora im Sauflingsund Erwachsenenstuhl. Zenfralblaft ftir Bakteriologie Parasitenkunde, Infektionskrankheiten und Hygiene, Abteilung 1.
  222. (1997). Viability of yoghurt and probiotic bacteria in yogurts made from commercial starter cultures.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.